- Home
- BEAT vs CVKD Comparison
BEAT vs CVKD Comparison
Compare BEAT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- CVKD
- Stock Information
- Founded
- BEAT 2015
- CVKD 2022
- Country
- BEAT United States
- CVKD United States
- Employees
- BEAT N/A
- CVKD N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BEAT Technology
- CVKD Health Care
- Exchange
- BEAT Nasdaq
- CVKD Nasdaq
- Market Cap
- BEAT 33.1M
- CVKD 29.5M
- IPO Year
- BEAT 2021
- CVKD 2023
- Fundamental
- Price
- BEAT $1.03
- CVKD $12.68
- Analyst Decision
- BEAT Buy
- CVKD Strong Buy
- Analyst Count
- BEAT 1
- CVKD 1
- Target Price
- BEAT $8.00
- CVKD $32.00
- AVG Volume (30 Days)
- BEAT 118.9K
- CVKD 31.2K
- Earning Date
- BEAT 08-13-2025
- CVKD 08-11-2025
- Dividend Yield
- BEAT N/A
- CVKD N/A
- EPS Growth
- BEAT N/A
- CVKD N/A
- EPS
- BEAT N/A
- CVKD N/A
- Revenue
- BEAT N/A
- CVKD N/A
- Revenue This Year
- BEAT N/A
- CVKD N/A
- Revenue Next Year
- BEAT N/A
- CVKD N/A
- P/E Ratio
- BEAT N/A
- CVKD N/A
- Revenue Growth
- BEAT N/A
- CVKD N/A
- 52 Week Low
- BEAT $0.91
- CVKD $5.70
- 52 Week High
- BEAT $3.48
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BEAT 40.15
- CVKD 58.32
- Support Level
- BEAT $0.91
- CVKD $10.14
- Resistance Level
- BEAT $1.32
- CVKD $11.30
- Average True Range (ATR)
- BEAT 0.12
- CVKD 0.89
- MACD
- BEAT 0.01
- CVKD 0.32
- Stochastic Oscillator
- BEAT 29.27
- CVKD 92.49
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.